Iron Chelation Therapy pp 185-203 | Cite as
ICL670A: Preclinical Profile
Abstract
Man is unable to actively eliminate iron from the body, once it has been acquired. Toxic and eventually lethal levels of iron accumulate as a result of repeated transfusions, e.g. in ß-thalassemia major, or due to excessive dietary iron uptake in anemias and hereditary hemochromatosis. Excess iron is deposited in the form of hemosiderins (insoluble “iron cores” of ferritin) mainly in the liver, spleen, many endocrine organs and in the myocardium. The exact mechanism of iron damage to these tissues is unknown, but it is established that organ failure correlates with iron burden in these tissues. Except for infectious diseases, cardiac complications are the major cause of death in ß-thalassemia major patients.
Keywords
Iron Chelator Liver Iron Concentration Marmoset Monkey Oral Toxicity Study Iron ExcretionPreview
Unable to display preview. Download preview PDF.
References
- 1.Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E., Harris, J.W. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major.New Engl. J. Med.1994,331, 567–573.CrossRefGoogle Scholar
- 2.Gabutti, V., Piga, A. Results of Long-term Iron Chelating Therapy.Acta Haematol.19969526–36.CrossRefGoogle Scholar
- 3.Olivieri, N.F.; Nathan, D.G.; MacMillan, J.H.; Wayne, A.S.; Liu, P.P.; McGee, A.; Martin, M.; Koren, G.; Koren, A.R. Survival in Medically Treated Patients with Homozygous ß-Thalassemia.New Engl. J. Med.1994,331, 574–578.CrossRefGoogle Scholar
- 4.Hams, W.R., Raymond, K.N., Weitl. F.L. Ferric Ion Sequestring Agents: The Spectrophotometric and Potentiometric Evaluation of Sulfonated Tricatecholate Ligands.J. Am. Chem. Soc.19811032667–2675.CrossRefGoogle Scholar
- 5.Bergeron, R.J., Wiegand, J., Dionis, J.B., Egli-Karmakka, M., Frei, J., Huxley-Tencer, A., Peter, H.H. Evaluation of Desferrithiocin and its Synthetic Aanalogues as Orally Effective Iron Chelators.J. Med. Chem.1991342072–2078.CrossRefGoogle Scholar
- 6.Pippard, M.J., Groves, M.J., Hider, R.C. Effects of Hydroxypyridinone Chelating Agents on Internal Iron Exchange.Br. J. Haematol.1991,77 (Suppl1), 39.Google Scholar
- 7.Finch, C.A., Ragan, H.A., Dyer, I.A., Cook, J.D. Body Iron Loss in Animals.Proc. Soc. Exp. Biol. Med.1978159335–338.Google Scholar
- 8.Bergeron, R.J., Streiff, R.R., Creary, E.A., Daniels, R.D. Jr., King, W., Luchetta, G., Wiegand, J., Moerker, T., Peter, H.H. A Comparative Study of the Iron-clearing Properties of Desferrithiocin Analogues with Desferrioxamine B in a Cebus Monkey Model.Blood1993, 15, 81(8): 2166–2173.Google Scholar